FBC Holdings (Pink Sheets: FBCD) recently announced a transition from a development company to a revenue ready/building company. The recent additions of Todd Wahnish and Mike Kern, along with Steven Miller, have put the company in a strategically strong position to execute its business plan. This business plan has evolved from focusing solely on toy manufacturing to something much bigger than ever envisioned.
This is only the tip of the iceberg that makes us so excited that we are finally at the point to go live. In the coming days we plan to disclose more of our new business plan, in addition to announcing the name of our site, and ultimately going live. We will be providing investors in the near future more information on how our business plan will drive revenues thus resulting in significant long term shareholder growth. http://finance.yahoo.com/news/fbc-business-plan-110000992.html
Say Hello to Better Diabetes Management
On April 13, PositiveID Corporation (OTCBB: PSID) began taking pre-orders for its FDA-cleared iglucose(R) mobile health system for diabetes management from interested consumers providers. iglucose is a unique device that simplifies the process of diabetes management making it easier for patients to accurately and effectively self-manage their glucose levels for better health. With approximately 26 million diabetic people in US, the potential impact of this device is astounding.
What Is iglucose?
iglucose is a unique device that communicates data wirelessly from glucometers to the iglucose diabetes management portal, allowing diabetes patients to share data in real time with family members and health care professionals. By eliminating the need for log keeping, iglucose puts diabetes management back in the hands of the patients.
Hemp and Medical Marijuana Are Big Business
In the United States alone, marijuana is estimated to be a $110 billion market, with the medical market making up nearly $17 billion. Medical Marijuana Inc. (MJNA), the first publicly held company to emerge from the medical marijuana and industrial hemp market, has experienced an incredible 4000% increase in revenue, with even more growth expected in the future.
Amazingly, there are more than 55,000 uses for medical marijuana and industrial hemp. Since all of these industries are underdeveloped, undercapitalized and not being utilized fully, the potential for growth and expansion has yet to be realized.
Once again, PositiveID Corporation aims to transforms the medical industry, this time with a new product called Dragonfly. This innovative company has just received a U.S. Patent for its most rapid molecular diagnostic testing device to date, the Dragonfly (TM) Rapid MDx Cartridge‐based diagnostic system. This amazing new medical technology provides the ability to deliver accurate results in less than half an hour. Imagine knowing the results of your medical tests during the same doctor’s visit, only a few minutes after examination. The future has arrived with Dragonfly. Now, patients can receive a rapid diagnosis in a fraction of the time required for current medical testing procedures.
The Waiting Game of Current Diagnostic Practices
Current diagnostic practices involve lengthy waiting periods often several days long. Without molecular diagnostics, samples must be identified according to their pathology or appearance under a microscope. For example, it can take up to 3 days to get results back from a culture to identify a strep throat infection. Delaying diagnosis usually means delaying treatment. In some cases, this delay of treatment can cause serious complications.
With an estimated 285 million people worldwide suffering from diabetes, the disease has become an epidemic and the problem continues to grow at a startling rate. As the second leading cause of death in the United States, more than 26 million U.S. residents have been diagnosed with diabetes. Advances in effective management are more necessary than ever before. Luckily, an innovative company called PositiveID Corporation (OTCBB: PSID) is developing three new products that could drastically improve the world of diabetes management.
EasyCheck™, a hand-held device, checks glucose levels in exhaled breath, thus making the traditional finger-pricking method unnecessary. A second product, cleverly called iglucose™, communicates wirelessly with a diabetic’s glucometer, automatically downloading glucose data to a central location for further analysis. Finally, GlucoChip™ uses RFID technology combined with a tiny embedded bio-sensor system to measure glucose levels in the body in real-time, making it easier than ever to manage your health.
Since the tragic attacks of September 11th, 2001, and the terrifying Amerithrax case, the world has become ever so aware of the threat of biological warfare and how very real this threat is. However, innovative companies like PositiveID Corporation (OTCBB: PSID) and their subsidiary MicroFluidic Systems have developed a bioagent detection device that will change how our government and military fight biowarfare.
So, what is bioagent detection anyway? Bioagent detection devices test the air for the presence of deliberately-released biological pathogens that are dangerous enough to be used as a biological weapon. Bacillus anthracis, perhaps the most commonly-known bioagent, causes Anthrax, a typically fatal disease. Because some of these hazardous agents can be made from readily-found ingredients, the need for solid protection against these types of deadly attacks continues to grow.